$43.01
0[0.00%]
At close: May 13
$43.01
0[0.00%]
PreMarket: 4:00PM EDT
Apellis Pharmaceuticals
(NASDAQ:APLS)Latest News for Apellis Pharmaceuticals Stock (NASDAQ:APLS)
Apellis Pharmaceuticals Stock (NASDAQ: APLS)
Categories: All
Wednesday, May 08, 2024
- Citigroup Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $60Benzinga Newsdesk - 5 days ago
- HC Wainwright & Co. Reiterates Buy on Apellis Pharmaceuticals, Maintains $92 Price TargetBenzinga Newsdesk - 5 days ago
- In-Depth Examination Of 14 Analyst Recommendations For Apellis PharmaceuticalsBenzinga Insights - 5 days ago
- UBS Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $85Benzinga Newsdesk - 5 days ago
- Needham Reiterates Buy on Apellis Pharmaceuticals, Maintains $85 Price TargetBenzinga Newsdesk - 5 days ago
Tuesday, May 07, 2024
Tuesday, April 30, 2024
Monday, April 29, 2024
Friday, April 26, 2024
- HC Wainwright & Co. Reiterates Buy on Apellis Pharmaceuticals, Maintains $92 Price TargetBenzinga Newsdesk - Apr 26, 2024, 2:22PM
- Apellis Pharmaceuticals shares are trading higher after the European Medicines Agency resets Pegcetacoplan review for geographic atrophy to day 180 of initial assessment.Benzinga Newsdesk - Apr 26, 2024, 7:22AM
- European Medicines Agency Has Reset The Review Of Apellis Pharmaceuticals' Intravitreal Pegcetacoplan For Geographic Atrophy To The Last Phase Of The Initial Assessment (Day 180). Apellis Anticipates An Opinion From CHMP No Later Than July 2024Benzinga Newsdesk - Apr 26, 2024, 7:19AM
Thursday, April 25, 2024
Thursday, April 18, 2024
Wednesday, April 17, 2024
Monday, April 15, 2024
Wednesday, April 10, 2024
Tuesday, April 09, 2024
Friday, March 29, 2024
Wednesday, March 27, 2024
Friday, March 15, 2024
Wednesday, March 06, 2024
Monday, March 04, 2024
Wednesday, February 28, 2024
- Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (18 Ratings)Benzinga Insights - Feb 28, 2024, 3:01PM
- HC Wainwright & Co. Reiterates Buy on Apellis Pharmaceuticals, Maintains $92 Price TargetBenzinga Newsdesk - Feb 28, 2024, 12:55PM
- ICU Medical To Rally Around 28%? Here Are 10 Top Analyst Forecasts For WednesdayAvi Kapoor - Feb 28, 2024, 8:07AM
- Wedbush Maintains Neutral on Apellis Pharmaceuticals, Raises Price Target to $67Benzinga Newsdesk - Feb 28, 2024, 7:48AM
Tuesday, February 27, 2024
Thursday, February 22, 2024
Friday, February 16, 2024
Tuesday, February 06, 2024
Monday, February 05, 2024
- $1000 Invested In Apellis Pharmaceuticals 5 Years Ago Would Be Worth This Much TodayBenzinga Insights - Feb 5, 2024, 1:30PM
- Pinterest To Rally Over 20%? Here Are 10 Top Analyst Forecasts For MondayAvi Kapoor - Feb 5, 2024, 8:09AM
- Jefferies Upgrades Apellis Pharmaceuticals to Buy, Raises Price Target to $80Benzinga Newsdesk - Feb 5, 2024, 5:21AM
Tuesday, January 30, 2024
Friday, January 26, 2024
Wednesday, January 24, 2024
Wednesday, January 17, 2024
- Baird Maintains Outperform on Apellis Pharmaceuticals, Raises Price Target to $81Benzinga Newsdesk - Jan 17, 2024, 2:30PM
- Netflix To Rally Over 13%? Here Are 10 Top Analyst Forecasts For WednesdayAvi Kapoor - Jan 17, 2024, 8:19AM
- HC Wainwright & Co. Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $92Benzinga Newsdesk - Jan 17, 2024, 6:23AM
Monday, January 15, 2024
Friday, January 12, 2024
- Apellis Pharmaceuticals shares are trading higher after Wedbush maintained a Neutral rating on the stock and raised its price target from $39 to $60.Benzinga Newsdesk - Jan 12, 2024, 2:50PM
- Wedbush Maintains Neutral on Apellis Pharmaceuticals, Raises Price Target to $60Benzinga Newsdesk - Jan 12, 2024, 8:18AM